Latigo Biotherapeutics files for IPO on Nasdaq under ticker LTGO

Latigo Biotherapeutics, Inc. filed an S-1 registration statement with the SEC on July 17, 2026 for an initial public offering of common stock, seeking to list on The Nasdaq Global Select Market under the symbol "LTGO." Goldman Sachs & Co. LLC, Jefferies, Leerink Partners and Guggenheim Securities are named as underwriters.¹

The company describes itself as a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction.¹ Its lead candidate, LTG-001, is an oral Nav1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for acute pain, currently in development for moderate to severe acute pain including postoperative pain, intended for use as needed for up to 30 days.¹

In its randomized, placebo and comparator-controlled abdominoplasty trial of 343 patients, high dose LTG-001 met its primary endpoint of Summed Pain Intensity Difference from 0 to 48 hours, achieving a 62.1-point improvement versus placebo (p<0.001), numerically exceeding the 40.9-point improvement seen with the opioid comparator Vicodin (p=0.001).¹ The trial also showed 52.3% of high-dose LTG-001 patients remained opioid-free during the 48-hour period versus only 22.1% in the placebo group.¹

The company said it plans to initiate a placebo-controlled Phase 3 trial in bunionectomy patients and an open-label Phase 3 safety trial in the second half of 2026, with topline results expected in the second half of 2027.¹

Financially, net losses were approximately $61.2 million and $109.2 million for 2024 and 2025 respectively, with an accumulated deficit of approximately $266.1 million as of March 31, 2026.¹ The company reported having raised approximately $321.5 million since inception¹ and held approximately $54.8 million in cash as of June 30, 2026.¹